BioMarin and Serono Announce Positive Results From Phase 3 Clinical Study of Phenoptin for PKU
March 15 2006 - 4:00PM
PR Newswire (US)
All Primary and Secondary Endpoints Met NOVATO, Calif. and GENEVA,
March 15 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc.
(Nasdaq and SWX: BMRN) and Serono (virt-x: SEO and NYSE: SRA)
announced today positive results of a Phase 3, double-blind,
placebo-controlled clinical study of Phenoptin(TM) (sapropterin
dihydrochloride), an investigational oral small molecule for the
treatment of phenylketonuria (PKU). Results confirm that all
pre-specified primary and secondary endpoints were met and data
from the Phase 3 study demonstrate a statistically significant
reduction at six weeks in blood phenylalanine (Phe) levels (p